Charles Schwab
MXCT icon

Charles Schwab’s MaxCyte MXCT Stock Holding History

Charles Schwab’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$144K Sell
117,192
-211,459
-64% -$211K ﹤0.01% 3399
2026
Q1 		$231K Sell
328,651
-41,050
-11% -$38.3K ﹤0.01% 3291
2025
Q4 		$573K Buy
369,701
+117,471
+47% +$188K ﹤0.01% 3118
2025
Q3 		$399K Sell
252,230
-44,238
-15% -$76.9K ﹤0.01% 3232
2025
Q2 		$646K Sell
296,468
-3,266
-1% -$7.91K ﹤0.01% 3040
2025
Q1 		$818K Buy
299,734
+7,754
+3% +$30.6K ﹤0.01% 2907
2024
Q4 		$1.21M Sell
291,980
-7,693
-3% -$29.1K ﹤0.01% 2841
2024
Q3 		$1.17M Buy
299,673
+761
+0.3% +$3.21K ﹤0.01% 2873
2024
Q2 		$1.17M Buy
298,912
+56,020
+23% +$241K ﹤0.01% 2869
2024
Q1 		$1.02M Sell
242,892
-851
-0.3% -$4K ﹤0.01% 2792
2023
Q4 		$1.15M Buy
243,743
+5,271
+2% +$20.5K ﹤0.01% 2788
2023
Q3 		$744K Hold
238,472
– – ﹤0.01% 2893
2023
Q2 		$1.09M Sell
238,472
-189
-0.1% -$869 ﹤0.01% 2741
2023
Q1 		$1.18M Buy
238,661
+5,516
+2% +$27.2K ﹤0.01% 2685
2022
Q4 		$1.27M Buy
233,145
+3,176
+1% +$19.5K ﹤0.01% 2706
2022
Q3 		$1.5M Buy
229,969
+38,797
+20% +$216K ﹤0.01% 2667
2022
Q2 		$905K Sell
191,172
-31,697
-14% -$156K ﹤0.01% 2833
2022
Q1 		$1.56M Buy
222,869
+15,047
+7% +$103K ﹤0.01% 2727
2021
Q4 		$2.12M Buy
207,822
+173,485
+505% +$1.86M ﹤0.01% 2691
2021
Q3 		$420K Buy
+34,337
New +$518K ﹤0.01% 3196

Other funds holding MXCT

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $128M AUM
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Charles Schwab's MXCT Position: Q2 2026 in Review

Charles Schwab reduced its MaxCyte (MXCT) stake by 64% in Q2 2026, selling an estimated $211K and leaving 117,192 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #3399.

Charles Schwab first reported a position in MXCT in Q3 2021 and has held it in 20 quarters since. The position peaked at $2.12M in Q4 2021. 123 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

  • Charles Schwab held 117,192 shares of MaxCyte worth $144K as of Q2 2026.
  • Charles Schwab sold 211,459 MaxCyte shares in Q2 2026, an estimated $211K.
  • MaxCyte made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3399 holding.
  • Charles Schwab first reported a position in MaxCyte in Q3 2021 and has held it in 20 quarters since.
  • Charles Schwab's MaxCyte position peaked at $2.12M in Q4 2021.
  • 123 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.